Effect of topical testosterone on bone mineral density in men: a systematic review and meta-analysis

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 224-247-Osteoporosis I
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-234
Dileep K Atluri*1 and Pratibha P Raghavendra2
1University Hospitals of Cleveland, 2University Hospitals, Case Medical Center, Cleveland, OH
Effect of topical testosterone on bone mineral density in men: a systematic review and meta-analysis


Introduction:  Testosterone deficiency puts aging men at higher risk of osteoporosis. Several forms of testosterone supplementation are currently available to clinician. The effect of topical testosterone supplementation on bone mineral density remains unclear.

Objective: To systematically review available randomized controlled trials and conduct meta analysis to evaluate the effect of topical testosterone on bone mineral density in men.

Data sources: Pubmed and Cochrane central register of controlled trials

Study eligibility criteria: Randomized controlled trials comparing topical testosterone with placebo in adult male patients, Minimum duration of therapy 6 months.

Study appraisal and synthesis methods: 4 randomized, placebo controlled trials were included. Primary outcomes assessed were bone mineral density (BMD) at lumbar spine and femoral neck. Meta analysis was conducted using Revman 5 software. Random effects model was used in meta analysis and standardized mean difference (SMD) was used as a summary statistic.

Results: 4 studies including 289 patients were included. In trials of topical testosterone vs placebo, allocation to topical testosterone did not significantly increase BMD.

Limitations: Some of the included studies did not specify intention to treat (ITT) population and had significant loss to follow-up. Duration of therapy varied from 6 months to 36 months. Additional studies addressing the same question may have been missed in the search. Patients with different levels of hypogonadism/pre treatment testosterone concentration were included.

Conclusions: Trials with clinical data such as bone fracture incidence are needed.

Nothing to Disclose: DKA, PPR

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm